|
|
| Source: PR Newswire 01-16-2019 06:00:57 |  (Cellenkos), an early stage clinical biotechnology company developing umbilical cord blood-derived T-regulatory (Treg) cellular therapies for the treatment of autoimmune diseases and inflammatory disorders, announced today the appointment of Elizabeth Read, M.D. as Chief Technology Officer and Chemistry, Manufacturing, and Controls (CMC) Advisor overseeing product development, manufacturing and regulatory affairs.
Read All |
| | | | | | | | |
|
